DiagnoCure Retains JMP to Help with Lab Business | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – DiagnoCure this week said that it has retained the financial services firm JMP Securities to help it increase business for its DiagnoCure Oncology Laboratories.

In a statement, Yves Fradet, president and chief medical officer of DiagnoCure, added that JMP will help the company "determine the most effective method to roll out our colorectal cancer disease management program."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.